EGFR and acne: The safety profile of third‐generation EGFR‐TKIs was consistent with the primary adverse events report (Table S3), which included rash and acne (1 patient, 2.2%), nausea (1 patient, 2.2%), bone marrow suppression (1 patient, 2.2%), diarrhea (1 patient, 2.2%), and oral ulcers (1 patient, 2.2%) in the third‐generation EGFR‐TKIs group.